A Multicenter, 48-week, Open-label Extension Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis.
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs Bimekizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions
- Sponsors UCB Biopharma
- 29 Mar 2019 Status changed from active, no longer recruiting to completed.
- 12 Feb 2019 Planned End Date changed from 1 Feb 2019 to 1 Mar 2019.
- 12 Feb 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Mar 2019.